235 related articles for article (PubMed ID: 9523178)
1. Antisense oligonucleotides.
Kashihara N; Maeshima Y; Makino H
Exp Nephrol; 1998; 6(1):84-8. PubMed ID: 9523178
[TBL] [Abstract][Full Text] [Related]
2. Fast and accurate determination of sites along the FUT2 in vitro transcript that are accessible to antisense oligonucleotides by application of secondary structure predictions and RNase H in combination with MALDI-TOF mass spectrometry.
Gabler A; Krebs S; Seichter D; Förster M
Nucleic Acids Res; 2003 Aug; 31(15):e79. PubMed ID: 12888531
[TBL] [Abstract][Full Text] [Related]
3. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis.
Vickers TA; Koo S; Bennett CF; Crooke ST; Dean NM; Baker BF
J Biol Chem; 2003 Feb; 278(9):7108-18. PubMed ID: 12500975
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic applications of antisense oligonucleotides in asthma and allergy.
Isidoro-García M; Dávila I
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):171-5. PubMed ID: 19075979
[TBL] [Abstract][Full Text] [Related]
6. Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology.
Crooke RM; Graham MJ
Methods Mol Biol; 2013; 1027():309-24. PubMed ID: 23912993
[TBL] [Abstract][Full Text] [Related]
7. Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice.
Hagedorn PH; Pontoppidan M; Bisgaard TS; Berrera M; Dieckmann A; Ebeling M; Møller MR; Hudlebusch H; Jensen ML; Hansen HF; Koch T; Lindow M
Nucleic Acids Res; 2018 Jun; 46(11):5366-5380. PubMed ID: 29790953
[TBL] [Abstract][Full Text] [Related]
8. Binary Antisense Oligonucleotide Agent for Cancer Marker-Dependent Degradation of Targeted RNA.
Drozd VS; Eldeeb AA; Kolpashchikov DM; Nedorezova DD
Nucleic Acid Ther; 2022 Oct; 32(5):412-420. PubMed ID: 35852843
[TBL] [Abstract][Full Text] [Related]
9. Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2'-deoxy-2'-fluoro-D-arabinose and 2'-deoxyribose nucleotides.
Lok CN; Viazovkina E; Min KL; Nagy E; Wilds CJ; Damha MJ; Parniak MA
Biochemistry; 2002 Mar; 41(10):3457-67. PubMed ID: 11876654
[TBL] [Abstract][Full Text] [Related]
10. Short-term and long-term modulation of gene expression by antisense therapeutics.
Sazani P; Vacek MM; Kole R
Curr Opin Biotechnol; 2002 Oct; 13(5):468-72. PubMed ID: 12459339
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of multiple-turnover capability of locked nucleic acid antisense oligonucleotides in cell-free RNase H-mediated antisense reaction and in mice.
Yamamoto T; Fujii N; Yasuhara H; Wada S; Wada F; Shigesada N; Harada-Shiba M; Obika S
Nucleic Acid Ther; 2014 Aug; 24(4):283-90. PubMed ID: 24758560
[TBL] [Abstract][Full Text] [Related]
12. Selective mRNA degradation by antisense oligonucleotide-2,5A chimeras: involvement of RNase H and RNase L.
Robbins I; Mitta G; Vichier-Guerre S; Sobol R; Ubysz A; Rayner B; Lebleu B
Biochimie; 1998; 80(8-9):711-20. PubMed ID: 9865493
[TBL] [Abstract][Full Text] [Related]
13. Discrimination between ribonuclease H- and ribonuclease L-mediated RNA degradation by 2'-O-methylated 2-5A-antisense oligonucleotides.
Cramer H; Player MR; Torrence PF
Bioorg Med Chem Lett; 1999 Apr; 9(7):1049-54. PubMed ID: 10230638
[TBL] [Abstract][Full Text] [Related]
14. Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro.
Veal GJ; Agrawal S; Byrn RA
Nucleic Acids Res; 1998 Dec; 26(24):5670-5. PubMed ID: 9837998
[TBL] [Abstract][Full Text] [Related]
15. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries.
Ho SP; Britton DH; Stone BA; Behrens DL; Leffet LM; Hobbs FW; Miller JA; Trainor GL
Nucleic Acids Res; 1996 May; 24(10):1901-7. PubMed ID: 8657572
[TBL] [Abstract][Full Text] [Related]
16. A hitchhiker's guide to antisense and nonantisense biochemical pathways.
Branch AD
Hepatology; 1996 Dec; 24(6):1517-29. PubMed ID: 8938189
[TBL] [Abstract][Full Text] [Related]
17. Antisense phosphorothioate oligonucleotides direct both site-specific and nonspecific RNAse H cleavage of in vitro synthesized p120 mRNA.
Weidner DA; Busch H
Oncol Res; 1994; 6(6):237-42. PubMed ID: 7865899
[TBL] [Abstract][Full Text] [Related]
18. Is irrelevant cleavage the price of antisense efficacy?
Stein CA
Pharmacol Ther; 2000 Mar; 85(3):231-6. PubMed ID: 10739877
[TBL] [Abstract][Full Text] [Related]
19. 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo.
Prakash TP; Johnston JF; Graham MJ; Condon TP; Manoharan M
Nucleic Acids Res; 2004; 32(2):828-33. PubMed ID: 14762210
[TBL] [Abstract][Full Text] [Related]
20. The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA.
Vickers TA; Crooke ST
Nucleic Acids Res; 2015 Oct; 43(18):8955-63. PubMed ID: 26384424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
